A Phase I/II Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases.
Phase of Trial: Phase I/II
Latest Information Update: 15 Sep 2015
At a glance
- Drugs Lacnotuzumab (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Adverse reactions
- Sponsors Novartis
- 04 Sep 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
- 04 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Oct 2008 Planned end date (Sep 2010) added as reported by ClinicalTrials.gov.